World First: CorWave’s Undulating Membrane Heart Pump Implanted in First Patient

First-of-its-kind heart pump implanted in Australia, based on a breakthrough wave membrane technology. Unlike existing devices, CorWave’s technology does not eliminate the effects of the native heartbeat and preserves the natural heart pulse. Early results suggest the pulsatility is preserved which could lead to a reduction of adverse events. The patient, suffering from advanced heart … [Read more…]

Bonerge Initiates Clinical Trial on Urolithin A and Fisetin for Sleep & Wellbeing

NEW YORK–(BUSINESS WIRE)–In 2025, Bonerge initiated a clinical trial (Registration #NCT06990256) investigating the effects of Urolithin A and Fisetin on sleep quality, targeting sleep disorders through the lens of ageing biology. This randomized, quadruple-blind (participants, healthcare providers, researchers, assessors), placebo-controlled study will enroll over 80 participants aged 45-70. They will be divided into four groups: … [Read more…]

Preceptis Medical Appoints Dave Carey as Chief Executive Officer to Lead Next Phase of Strategic Growth

MINNEAPOLIS–(BUSINESS WIRE)–Preceptis Medical, Inc., a commercial-stage medical technology company transforming pediatric ENT care, today announced the appointment of Dave Carey as Chief Executive Officer. Carey assumes leadership as the company accelerates toward full market release of its flagship product, the Hummingbird® Tympanostomy Tube System (TTS). “We are thrilled to welcome Dave Carey to Preceptis,” said … [Read more…]

Avvio Medical’s Microbubble Technology Reduces Complications and Shows Promise for Enhancing Laser Lithotripsy: AEROLITH Trial Results Published in The Journal of Urology

SAN FRANCISCO–(BUSINESS WIRE)–Avvio Medical Inc. today announced the publication of its AEROLITH randomized clinical trial in The Journal of Urology. Study highlights were presented at the 2025 American Urological Association (AUA) Annual Meeting in Las Vegas, Nevada. The AEROLITH study evaluated the safety and effectiveness of Acoustic Enhancer Microbubble Cavitation (AEMC) when used with ureteroscopic … [Read more…]

Vertex to Announce Second Quarter 2025 Financial Results on August 4th

BOSTON–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2025 financial results on Monday, August 4, 2025 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Vertex … [Read more…]

The Ngāi Tahu Research Centre Has Entered Into a Strategic Partnership With De-Extinction Company, Colossal Biosciences, and Sir Peter Jackson, to Resurrect the South Island Giant Moa and Other Taonga Species

The Ngāi Tahu Research Centre coordinated project aims to advance ecological restoration and develop tools for conservation in Te Waipounamu, New Zealand’s South Island TE WAIPOUNAMU/SOUTH ISLAND, New Zealand–(BUSINESS WIRE)–In a historic indigenous-coordinated initiative, the Ngāi Tahu Research Centre has entered into a collaboration with Colossal Biosciences, a Texas-based genetic engineering and de-extinction company, and … [Read more…]

SBB Research Group Foundation Awards Additional Grants to 3 Illinois Nonprofits

CHICAGO–(BUSINESS WIRE)–The SBB Research Group Foundation invited three prior grant recipients to share updates on their critical efforts to support the local community. The Foundation awarded additional grants to further each of the respective organizations’ missions (organizations listed alphabetically): Black Onyx Allstars (Chicago, IL) offers a culturally inclusive and empowering cheerleading experience that fosters community … [Read more…]

WELL Health Provides Corporate Update on Canadian Clinics Business, Reflecting Improved Guidance and an Expanded Credit Facility

WELL continues to demonstrate strong momentum through continued organic and inorganic growth and is pleased to announce that it is ahead of internal expectations and has updated its guidance for its Canadian Patient Services segment to over $450 million(1) in revenue and over $60 million(1) in Adjusted EBITDA(2) for fiscal 2025. WELL’s Canadian Clinics business … [Read more…]

BlueRock Therapeutics announces first patient receives investigational therapy in Phase 1/2a clinical trial of OpCT-001 for the treatment of primary photoreceptor diseases

OpCT-001 is the first iPSC-derived investigational cell therapy to be clinically tested for treating primary photoreceptor diseases Phase 1/2a trial, CLARICO, is a first-in-human, multisite, 2-part interventional trial to evaluate the safety, tolerability, and the effect on clinical outcomes of OpCT-001 Primary photoreceptor diseases are a subgroup of inherited retinal disorders that affect the structure … [Read more…]

Invivoscribe Expands Flow Cytometry Services to Accelerate CAR-T Immunotherapy Development and Regulatory Readiness with the Initiation of CERo Therapeutics Phase 1 Clinical Trial

SAN DIEGO–(BUSINESS WIRE)–#invivoscribe–Invivoscribe Inc., a global leader in precision diagnostics and measurable residual disease (MRD) testing, is proud to support CERo Therapeutics Holdings, Inc., an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms. Through this collaboration, LabPMM (Invivoscribe’s global reference laboratories) have customized their multiparametric … [Read more…]